Nantes, 12 June 2017, 18 hours – OSE Immunotherapeutics AG (ISIN: FR0012127173; Mnémo: OSE), announced today the signing of a research collaboration agreement multi-year with the Memorial Sloan Kettering Center (MSK) in New York. This collaboration focuses on OSE-703 (Effi-3), a cytotoxic monoclonal antibody that targets the alpha chain of the receptor of interleukin-7 (IL-7R).
Download the free guide
Boost your gains
This collaboration will focus on a program of research, using DARE-703 (Effi-3), a humanized monoclonal antibody directed against the extracellular receptor alpha chain of the interleukin-7 (CD127), and cytotoxic to human cells expressing CD127.
The research program will be conducted by Dr. Prasad S. Adusumilli, FACS, thoracic surgeon and expert in the immunology of the tumour, and in particular a specialist in immunotherapy cells
SINCE T (chimeric antigen receptor T -cell).
The objective of this research collaboration is to assess OSE-703, immunotherapy targeting the receptor to IL-7 in solid tumors with a first model in lung cancer non-small cell (NSCLC, Non-Small Cell Lung Cancer). In effect, a large cohort of patients with NSCLC* has shown that the IL-7 receptor was overexpressed in this type of cancer and was associated with a poor prognosis.
“We are very pleased to be working with one of the world centres of the most renowned in the research and treatment of cancer, and to team up with Dr. Prasad Adusullimi. Its expertise in immuno-oncology, and in particular in the area of the cells AS T, associated to the therapeutic potential of OSE-703 will enable this research program to achieve major progress on the efficacy profile of the product and its prospects of development “, declares Dominique Costantini, ceo, OSE Immunotherapeutics.
* Suzuki et al, J Clin Oncol. 2013 Feb 1; 31(4): 490-498.
ABOUT DARE IMMUNOTHERAPEUTICS
Our ambition is to become one of the world leaders in immunotherapy activation and regulation
DARE Immunotherapeutics) is a biotechnology company specializing in the activation and immune regulation in immuno-oncology, autoimmune diseases and in transplantation.
The company has a balanced portfolio, with a risk profile that is diverse, ranging from the clinical phase to registration of R&D :
??? Tedopi®, a combination of 10 néoépitopes optimized to induce an activation response in immuno-oncology – ongoing Phase 3 registration in the lung cancer advanced in Europe and the United States, in patients with HLA-A2+ – Status orphan to the United States, Registration as provided for in 2019 – A Phase 2 study of Tedopi® in combination with a checkpoint inhibitor in NSCLC is planned in 2017.
??? DARE-172 (Effi-DEM), checkpoint of the new generation targeting cells of the myeloid suppressor via receptor SIRP-? – In preclinical in several cancer models.
In autoimmune diseases and transplantation :
??? FR104, immunotherapy antagonist of the CD28 – Results of Phase 1 positive – refers to autoimmune diseases, and transplantation – Licensed to Janssen Biotech Inc. for further clinical development.
??? DARE-127 (Effi-7), immunomodulatory receptor antagonist to interleukin-7 – preclinical in inflammatory bowel disease and other autoimmune diseases – Option license agreement with Servier for the development and commercialization of the product.
In the light of medical needs targeted, these products have a real potential blockbuster and make the company the ability to enter into global agreements at different stages of their development with major pharmaceutical players.
DARE Immunotherapeutics seeks the field of immunotherapy, a very attractive market in full expansion. The immunotherapy of cancer may represent to the year 2023, nearly 60% of treatments, compared to less than 3% at the present time* and the market is estimated is estimated to be $ 67 billion by 2018**.
There are more than 80 autoimmune diseases that represent an important market integrating of the major players in the pharmaceutical industry, with sales in excess of 10 billion euros for the main products. The medical need is still largely unfulfilled and will require the provision of new products to control the immune system’s innovative and responsive.
*Citi Research Equity
Download the free guide
Boost your gains